Kanada - anglų - Health Canada

csl behring canada inc - streptokinase - powder for solution - 750000unit - streptokinase 750000unit - thrombolytic agents

Kanada - anglų - Health Canada

csl behring canada inc - streptokinase - powder for solution - 1500000unit - streptokinase 1500000unit - thrombolytic agents

Kanada - anglų - Health Canada

csl behring canada inc - streptokinase - powder for solution - 250000unit - streptokinase 250000unit - thrombolytic agents

Australija - anglų - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - alteplase -

Singapūras - anglų - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - aprotinin - injection - 500000 kiu/50 ml - aprotinin 500000 kiu/50 ml

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - acenocoumarol - oral tablet - 1mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - acenocoumarol - oral tablet - 1mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 5000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - white shrimp -